The Liphook Equine Hospital, Liphook, UK.
Equine Vet J. 2013 Nov;45(6):751-4. doi: 10.1111/evj.12068. Epub 2013 Apr 22.
Metformin is a potential therapeutic agent for the treatment of insulin resistance (IR). In laboratory animals, orally administered metformin reduces intestinal glucose absorption and may therefore affect insulinaemic responses to oral carbohydrate ingestion.
To determine whether pretreatment with metformin reduces plasma glucose concentration and insulin responses following consumption of dextrose in horses.
Therapeutic cross-over study.
Seven healthy Standardbred and Thoroughbred geldings were subjected to an oral dextrose challenge test on 4 occasions: with and without metformin, before and after induction of IR with dexamethasone. Metformin was administered by nasogastric tube at 30 mg/kg bwt 1 h before administration of dextrose. Glucose and insulin concentrations in plasma/serum were measured at regular intervals during each test. Linear mixed models were specified for each predetermined outcome variable, and for each model the 'treatment' was included as a fixed effect with 4 categorical levels (none, metformin, dexamethasone and dexamethasone with metformin) and horse accounted for as a random effect.
In healthy horses, the administration of metformin resulted in a statistically significant reduction in peak glucose concentration (P = 0.002), area under the glucose curve (P<0.001) and insulin concentration 120 min after dextrose administration (P = 0.011). Following the induction of IR, administration of metformin was associated with significant differences in peak glucose concentration (P<0.001), the percentage increase in glucose concentration (P = 0.010), the area under the glucose curve (P<0.001) and insulin concentration at 120 min (P = 0.034) and 150 min after dextrose administration (P = 0.014).
Metformin resulted in reduced glycaemic and insulinaemic responses both in healthy horses and in horses with experimentally induced IR.
Metformin may benefit horses with naturally acquired IR by reducing glycaemic and insulinaemic responses to dietary nonstructural carbohydrates. Further investigations into the mechanisms of action of metformin in horses and controlled clinical trials are warranted.
二甲双胍是治疗胰岛素抵抗(IR)的一种潜在治疗药物。在实验动物中,口服给予二甲双胍可减少肠道葡萄糖吸收,因此可能会影响口服碳水化合物摄入后的胰岛素反应。
确定在给予马匹葡萄糖前预先给予二甲双胍是否会降低葡萄糖浓度和胰岛素反应。
治疗交叉研究。
7 匹健康的标准马和纯血马在 4 次口服葡萄糖挑战测试中接受了测试:使用和不使用二甲双胍,以及使用和不使用地塞米松诱导 IR 前后。在给予葡萄糖前 1 小时,通过鼻胃管给予二甲双胍 30mg/kg 体重。在每次测试期间,定期测量血浆/血清中的葡萄糖和胰岛素浓度。对于每个预定的结果变量,指定了线性混合模型,并且对于每个模型,“治疗”被包括为具有 4 个分类水平(无、二甲双胍、地塞米松和地塞米松加二甲双胍)的固定效应,并且马被视为随机效应。
在健康的马匹中,给予二甲双胍可使峰值葡萄糖浓度(P=0.002)、葡萄糖曲线下面积(P<0.001)和 120 分钟后胰岛素浓度(P=0.011)显著降低。在诱导 IR 后,给予二甲双胍与峰值葡萄糖浓度(P<0.001)、葡萄糖浓度增加百分比(P=0.010)、葡萄糖曲线下面积(P<0.001)和 120 分钟后胰岛素浓度(P=0.034)和 150 分钟后胰岛素浓度(P=0.014)显著不同。
二甲双胍可降低健康马匹和实验性诱导 IR 马匹的血糖和胰岛素反应。
二甲双胍可通过降低对饮食非结构性碳水化合物的血糖和胰岛素反应,使自然发生 IR 的马匹受益。需要进一步研究二甲双胍在马中的作用机制,并进行对照临床试验。